Grossman William — SEC insider filings
SEC reporting owner CIK 1730229. 14 insider filings on record with FilingPulse; latest filed 2026-09-24.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2020-10-05 to 2026-09-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 5,102 shares, $10,051 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 6 legs across 4 filings — 15,442 shares, $439,338 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
- Largest priced transaction: sale of 4,133 shares @ $31.37 ($129,652) in Arcus Biosciences, Inc., filed 2021-04-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | Chief Medical Officer | 6 | — | 6 legs · 15,442 sh · $439,338 | 4 |
| enGene Therapeutics Inc. (ENGN) | Interim Chief Medical Officer, Director | 3 | 1 leg · 5,102 sh · $10,051 | — | 3 |
| Day One Biopharmaceuticals, Inc. (DAWN) | Director | 5 | — | — | 12 |
Insider filings — Grossman William
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-24 | 4 | enGene Therapeutics Inc. (ENGN) | Purchase (P): 5,102 @ $1.97 | EDGAR |
| 2026-06-17 | 4 | enGene Therapeutics Inc. (ENGN) | Grant/award (A): 31,000 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Disposition to issuer (D): 66,660 (derivative) · Disposition to issuer (D): 32,335 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2025-11-07 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Disposition to issuer (D): 66,660 (derivative) @ $0 · Grant/award (A): 66,660 (derivative) @ $0 · Disposition to issuer (D): 32,335 (derivative) @ $0 · Grant/award (A): 32,335 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Grant/award (A): 22,500 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Grant/award (A): 32,335 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Grant/award (A): 66,660 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Arcus Biosciences, Inc. (RCUS) | Sale (S): 3,047 @ $24.13 · Sale (S): 127 @ $24.77 · Sale (S): 3,891 @ $23.68 | EDGAR |
| 2021-04-26 | 4 | Arcus Biosciences, Inc. (RCUS) | Sale (S): 4,133 @ $31.37 | EDGAR |
| 2021-03-18 | 4 | Arcus Biosciences, Inc. (RCUS) | Sale (S): 2,127 @ $35.03 | EDGAR |
| 2021-01-20 | 4 | Arcus Biosciences, Inc. (RCUS) | Grant/award (A): 18,750 @ $0 · Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
| 2020-12-18 | 4 | Arcus Biosciences, Inc. (RCUS) | Sale (S): 2,117 @ $31.35 | EDGAR |
| 2020-10-05 | 4 | Arcus Biosciences, Inc. (RCUS) | Grant/award (A): 100,000 @ $0 · Grant/award (A): 100,000 (derivative) @ $17 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1730229 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs